NCT04615039
Withdrawn
Not Applicable
Post Market Clinical Follow-Up Study for MicroPort PROFEMUR® Preserve Classic Femoral Stem
ConditionsJoint Diseases
Overview
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- MicroPort Orthopedics Inc.
- Primary Endpoint
- Component Survivorship
Overview
Brief Summary
Sponsor is conducting this post market clinical study to evaluate the safety and effectiveness of its PROFEMUR® Preserve Classic Femoral Stem. This type of study is required by regulatory authorities for all devices that have been approved in Europe (EU) to evaluate the medium and long-term clinical evidence. This study has been designed in accordance with MEDDEV2.12/2 (European Medical Device Vigilance System) rev2 and ISO (International Organization of Standardization) 14155:2011 guidelines.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has previously undergone or currently has been determined to undergo a primary THA with the study component MPO PROFEMUR® Preserve Classic Stem combined with any type of polyethylene or ceramic acetabular shells, acetabular liners and femoral heads.
- •Has previously undergone or currently has been determined to undergo a primary THA for any of the following:
- •non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia;
- •inflammatory degenerative joint disease such as rheumatoid arthritis;
- •correction of functional deformity
- •Willing and able to complete required study visits and assessments through the 10 year postoperative follow-up visit.
- •Previously implanted subjects must be enrolled within 3 years (+ 6 months) of their primary THA implantation.
Exclusion Criteria
- •Skeletally immature (less than 21 years of age) at time of implantation
- •Has or had an overt infection at the time of implantation
- •Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation
- •Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation
- •Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
- •Has or had neuropathic joints
- •Has or had hepatitis or HIV infection
- •Has or had a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing
- •Has or had a revision procedure(s) where other treatments or devices have failed; and treatment of fractures that are unmanageable using other techniques
- •Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
Outcomes
Primary Outcomes
Component Survivorship
Time Frame: 10 years post-operative
To estimate component survivorship of the PROFEMUR® Preserve Classic Femoral Stem at 1, 3, 5, 7, 10 years.
Secondary Outcomes
- Subject Satisfaction as assessed by Satisfaction Survey(10 years post-operative)
- To assess subject safety(10 years post-operative)
- HOOS Functional Scores(10 years post-operative)
- Subject Satisfaction as assessed by Forgotten Joint Score(10 years post-operative)
- EQ-5D-5L Functional Scores(10 years post-operative)
- Radiolucencies(10 years post-operative)
- To assess device tolerability within subject(10 years post-operative)
Investigators
Similar Trials
Enrolling By Invitation
Not Applicable
Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCKKnee OsteoarthritisNCT04145401MicroPort Orthopedics Inc.45
Enrolling By Invitation
Not Applicable
Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral StemJoint DiseasesNCT04147559MicroPort Orthopedics Inc.150
Completed
Not Applicable
LifeVest Safety and Efficacy in Real Life Settings in FranceSudden Cardiac DeathLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasNCT03319160Zoll Medical Corporation1,164
Completed
Not Applicable
A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense StrongJawline Contour DeficitNCT06562075Bohus Biotech AB114
Active, not recruiting
Not Applicable
Avenir® Cemented Hip Stem - PMCFPrimary OsteoarthritisPost-Traumatic Osteoarthritis of HipFemoral Neck FracturesFemoral Head NecrosisSequelae From Previous Hip SurgeryOsteotomiesCongenital Hip DysplasiaNCT03396224Zimmer Biomet100